| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Dihydrotanshinone I targets multiple cellular pathways including acetylcholinesterase, bacterial enzymes, and cancer cell survival pathways; it exhibits potent anti-cancer activity through induction of apoptosis, cell cycle arrest, and cytotoxic effects on tumor cells.
|
|---|---|
| ln Vitro |
Dihydrotanshinone I (10 nM) inhibits NADPH oxidase 4 (NOX4) and lectin-like ox-LDL receptor 1 (LOX-1) in human umbilical vein endothelial cells (HUVEC) that have been activated with lipopolysaccharide (LPS). expression, ox-LDL endocytosis, generation of reactive oxygen species (ROS), nuclear translocation of NF-κB, and monocyte labeling [1]. In HCT116 cells, dihydrotanshinone I produces cytokines that are dependent on caspase. Dihydrotanshinone I-induced cell induction was totally inhibited by concentrations of the dihydrotanshinone I-inducing agent and by ROS-dependent Z-VAD-fmk. Orthopedic treatment of Z-LEHD-fmk greatly prevented dihydrotanshinone I-induced cell induction, whereas Z-IETD-fmk only marginally inhibited it. Apoptosis produced by dihydrotanshinone I is markedly increased by caspase-2 knockdown [3].
In vitro studies demonstrate that Dihydrotanshinone I exhibits potent cytotoxic and apoptosis-inducing effects on various cancer cell lines, including chemosensitive ovarian cancer cells, with activity observed in both platinum-sensitive and platinum-resistant settings. |
| ln Vivo |
Serum dye profiles were changed, the oxidative center was reduced, the central core area shortened, and ApoE-/- atherosclerotic plaques were considerably segmented by DHT (10 and 25 mg/kg). In the aorta, DHT strongly inhibits LOX-1. Treatment with 1, 2, or 4 mg/kg of dihydrotanshinone I has been shown to ameliorate myocardial enzyme spectrum and histological abnormalities, decrease infarct size, and enhance sparse myocardial reperfusion. modifications, controlling associated proteins and lowering the synthesis of 20-HETE [2].
In vivo efficacy has been demonstrated in animal models where Dihydrotanshinone I shows anti-tumor activity, though detailed in vivo pharmacokinetic and efficacy data are more extensively reported for other tanshinones; it also exhibits antibacterial activity against Staphylococcus aureus. |
| Enzyme Assay |
The in vitro enzyme assay for acetylcholinesterase inhibition involves incubating Dihydrotanshinone I with acetylcholinesterase enzyme and acetylthiocholine substrate, measuring the production of thiocholine via Ellman's method (absorbance at 412 nm), with IC50 values calculated from inhibition curves.
|
| Cell Assay |
In vitro cell culture studies utilize cancer cell lines (e.g., ovarian cancer, breast cancer, leukemia cells) treated with Dihydrotanshinone I for 24-72 hours, with cell viability assessed by MTT or CCK-8 assays, apoptosis detected by Annexin V/PI staining and flow cytometry, and cell cycle analysis performed by propidium iodide staining.
|
| Animal Protocol |
In vivo animal experiments involve administering Dihydrotanshinone I to tumor-bearing mice (xenograft models) via intraperitoneal or intravenous injection, monitoring tumor volume and weight, assessing survival outcomes, and performing histopathological analysis of tumor tissues for apoptosis markers and proliferation indices.
|
| ADME/Pharmacokinetics |
Dihydrotanshinone I is a lipophilic compound with molecular weight 278.3 g/mol and formula C18H14O3; it is stable for up to 24 months when stored at 2-8°C, typically provided as a red needle crystal with purity >98% (HPLC).
|
| Toxicity/Toxicokinetics |
Toxicological studies indicate that Dihydrotanshinone I exhibits dose-dependent cytotoxicity; comprehensive toxicity profiles in animal models are limited, though related tanshinones show manageable toxicity at therapeutic doses; the compound is classified as a research product not for human use.
|
| References |
|
| Additional Infomation |
Dihydrotanshinone I is an abiran-type diterpenoid compound with anticoronavirus activity. It has been reported to be present in Salvia miltiorrhiza, Salvia miltiorrhiza var. mucilaginosa, and other organisms with relevant data. See also: Salvia miltiorrhiza root (partial).
Dihydrotanshinone I is a well-established bioactive natural product extensively studied for its pharmacological properties; it has not been approved for clinical use but serves as a lead compound for anticancer drug development and a reference standard for quality control of Danshen and related herbal products. |
| Molecular Formula |
C18H14O3
|
|---|---|
| Molecular Weight |
278.3020
|
| Exact Mass |
278.094
|
| CAS # |
87205-99-0
|
| PubChem CID |
11425923
|
| Appearance |
Brown to red solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
479.2±45.0 °C at 760 mmHg
|
| Melting Point |
214.0 to 218.0 °C
|
| Flash Point |
214.9±28.8 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.671
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
21
|
| Complexity |
533
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@H]1COC2=C1C(=O)C(=O)C3=C2C=CC4=C(C=CC=C43)C
|
| InChi Key |
HARGZZNYNSYSGJ-JTQLQIEISA-N
|
| InChi Code |
InChI=1S/C18H14O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-7,10H,8H2,1-2H3/t10-/m0/s1
|
| Chemical Name |
(1R)-1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione
|
| Synonyms |
Dihydrotanshinone I; 15,16-dihydrotanshinone I; DihydrotanshinoneI; (-)-Dihydrotanshinone I; Dihydrotanshinone-I; Tanshinone I, dihydro-; HSDB 8105
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2 mg/mL (~7.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5932 mL | 17.9662 mL | 35.9324 mL | |
| 5 mM | 0.7186 mL | 3.5932 mL | 7.1865 mL | |
| 10 mM | 0.3593 mL | 1.7966 mL | 3.5932 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
